
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc reported a significant increase in gross margin, rising approximately 80 basis points year-over-year to reach 79.8% in the second quarter of 2025, indicating improved profitability. Revenue growth was robust, with a year-over-year increase of around 23%, totaling $46.4 million, which reflects strong demand for the company's innovative surgical implant products. Additionally, the company experienced a notable expansion in its surgeon base, with a 25% increase in surgeons using its products and a corresponding rise in production by its sales representatives, contributing to overall sales momentum.
Bears say
The financial outlook for SI-BONE Inc. is negatively influenced by persistent pricing and procedure headwinds in the global spine market, which have resulted in overall growth rates slowing to the low-single digits. Additionally, the potential for payors to favor reimbursement for competitive products poses a significant risk, as this could lead to a decline in SI-BONE's market share within the sacroiliac joint fusion segment, adversely impacting the company's top-line revenue. Most industry players anticipate that these headwinds will continue, further depressing overall market growth and raising concerns about SI-BONE's future financial performance.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares